A recombinant adenovirus expressing human interferon 2b driven by the cytomegalovirus promoter, IACB, was shown to produce and secrete biologically active protein in vitro and in vivo. Intravenous administration of IACB in Buffalo rats resulted in circulating levels of biologically active human interferon at 70,000 international units / mL for up to 15 days. Distribution of interferon protein after IACB administration was different from that seen with the subcutaneous delivery of interferon protein. Higher levels of interferon protein were observed in liver and spleen after IACB delivery compared to protein delivery. The antitumor efficacy of IACB, as measured by suppression of tumor growth, was tested in athymic nude mice bearing established human tumor xenografts from different types of human cancer. Subcutaneous tumors most responsive to the intratumoral administration of IACB ranked as U87MG ( glioblastoma ) and K562 ( chronic myelogenous leukemia ), followed by Hep 3B ( hepatocellular carcinoma ) and LN229 cells ( glioblastoma ). Intravenous administration of IACB in animals bearing U87MG or Hep 3B xenografts was also effective in suppressing tumor growth, although to a lesser extent than the intratumoral administration. IACB was also tested in a metastatic model in beige / SCID mice generated with H69 ( small cell lung carcinoma ) cells and was found to prolong survival in tumor -bearing animals. This suggested that interferon gene delivery can be effective in suppressing tumor growth in a wide variety of cells. Cancer Gene Therapy ( 2001 ) 8, 788 -795 
A lpha interferons are cytokines with multiple biological activities that include antiproliferative, antiviral, and immunomodulatory properties. 1 Because of their strong antitumor properties, they have been used clinically to treat more than 14 different types of cancer that include some of the hemopoeitic malignancies ( hairy cell leukemia, chronic myelogenous leukemia, some B -and T-cell lymphomas ) and certain solid tumors (reviewed in Refs. 2, 3 ). Despite its widespread use, it is still not clear why some tumors respond to interferon protein therapy, whereas others do not. 4 In addition, the use of interferon has been shown to be associated with certain undesired side effects. 5 It is quite conceivable that an improved therapeutic effect may be achieved by using interferon in a gene therapy modality because it would allow for increased and sustained local regional concentrations of this cytokine while preventing a widespread distribution.
In recent years, interferon , delivered by using adenovirus, 6, 7 retrovirus, 8, 9 or nonviral vectors, 10, 11 has been shown to suppress tumor growth in nude mice to varying extents. We describe here the use of a replicationdeficient adenovirus expressing interferon 2b, and biodistribution of the expressed protein and its ability to inhibit growth of subcutaneous tumors derived from hepatocellular carcinoma ( Hep 3B ), glioblastoma (U87MG and LN229 ), and chronic myelogenous leukemia ( K562 ). In addition, a disseminated model generated in beige /SCID mice with small cell lung carcinoma ( H69 ) cells was also inhibited by interferon 2b gene delivery. Therefore, interferon gene delivery seems to present an effective approach to suppress tumor growth in a broad spectrum of tumors regardless of the tissue of origin or the genetic alterations therein.
MATERIALS AND METHODS

Cell lines and viruses
Hep 3B, Hep G2, U87MG, K562, and H69 cells were obtained from ATCC (Gaithersburgh, MD ). LN229, a glioblastoma cell line, was a gift from Dr. Nicolas de Tribolet. 12 Hep 3B and Hep G2 cells were derived from hepatocellular carcinoma (HCC ). U87MG cells were derived from glioblastoma, K562 cells were derived from chronic myelogenous leukemia, and H -69 cells were derived from small lung carcinoma. These cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 378C in a humidified air chamber with 7% CO 2 .
The following nomenclature was used for the recombinant adenoviruses. An adenovirus backbone deleted in early region 1 and part of early region 3 was used. 13 The promoter used was that from immediate early gene of human cytomegalovirus (CMV ). IACB is the E1 and partial E3 -deleted recombinant adenovirus expressing human interferon 2b. Control adenoviruses used were GFCB expressing green fluorescent protein, or ZZCB, which does not contain a transgene. These viruses were amplified in HEK293 cells and purified by column chromatography. 14 Particle concentration was determined by high -performance liquid chromatography. 15 Particle number was used as a measure of the amount of virus used because it represents a more accurate assessment of the concentration of virus. 16 Phosphate -buffered saline (BioWhittaker, Walkersville, MD ) was used as the ''vehicle control'' for in vivo studies.
Quantitation of interferon
A modification of the electrochemiluminescence (ECL ) immunoassay utilizing ORIGEN system 17 was used to quantitate interferon levels in cell supernatants, animal sera, and residual interferon in purified preparations of IACB. Recombinant interferon 2b produced in Escherichia coli ( Intron A; Schering-Plough, Kenilworth, NJ ) was used as the standard. Assays were performed by mixing 25 L of the standard, controls, and samples with 25 L of a ruthenylated murine mAb7N41 and 25 L of a biotinylated sheep anti -IFN -2b polyclonal antibody for 3 hours at room temperature. Next, 25 L of streptavidin -coated dyanbeads was added and samples re -agitated for an additional hour followed by a quenching step. Responses were monitored in relative ECL units. Interferon 2b concentrations were determined by interpolation from the standard curve.
Antiviral activity
The biological assay used to assess potency of interferon secreted from infected Hep G2 cells was based on its ability to protect cells from virus -induced cytopathic effect (CPE ). A549 cells, a human adenocarcinoma cell line, were plated at a density of 4.7Â10 4 /cm 2 in 100 L of complete media (DMEM with 4.5 g /L D -glucose supplemented with 10% fetal bovine serum ) in 96-well plates. Various dilutions of each standard (Intron A ) or supernatants from Hep G2 cells were added to designated wells. Plates were incubated for 4 hours prior to being challenged with murine encephalomyocarditis (EMC ) virus (strain 129b -VR ). Some wells containing A549 cells were either treated with EMC virus ( positive control for CPE ) or media without virus. Cells were then incubated for an additional 44 hours or until CPE developed. Viability of cells was assessed using the MTS colorimetric assay ( Promega, Madison, WI ) by measuring changes in absorbance (490 nm ) in a microplate spectrophotometer. Values for antiviral activity were determined by interpolation from an Intron A standard curve. Specific activity, expressed as international units per milligram, was calculated by dividing the biological activity assay results (international units / mL ) by the interferon concentration in each sample (mg /mL ).
Biodistribution
ICR mice, three per group, were injected intravenously with 1Â10 10 particles of IACB. After 2, 7, and 14 days postadministration, animals were sacrificed and different tissues were obtained. DNA and RNA were extracted from these tissues and used for real -time quantitative PCR for DNA and reverse transcription polymerase chain reaction ( RT-PCR ) for RNA. 18 The following primers were used. Forward primer: 5 0 -AACGGTACTCCGCCACC -3 0 ; reverse primer: 5 0 -GGCCCGGGAAGCTCTAGAC -3 0 ; probe: FAM -TCCGCATCGACCGGATCGGA -TAMRA. To study the distribution of interferon protein in different tissues, ICR mice were injected intravenously with 1.8Â10 9 , 9.2Â10 9 , and 4.6Â10 10 particles of IACB or 5 g of Intron A subcutaneously. At the times indicted, the animals were sacrificed, and different tissues were extracted and assayed for interferon.
Suppression of in vivo tumor growth using a xenograft models in nude mice Female Balb /c athymic nude mice ( Simonsen Laboratories, Gilroy, CA ) were injected subcutaneously with 1Â10 7 Hep 3B or K562 cells. For U87MG and LN229, 5Â10 6 cells were injected subcutaneously. Tumors were allowed to grow and establish until they had reached a size of about 80 mm 3 . Animals were then randomized and 1Â10 10 particles of IACB or control adenovirus in 100 L were administered intratumorally six times over a period of 2 weeks. Intravenous administration consisted of two injections of 1Â10 10 particles per dose. Tumor sizes were measured in three dimensions using a Vernier caliper and tumor volume was computed assuming a spherical geometry with radius equal to one half the average tumor dimension. Tumor sizes were measured two times a week and mice were monitored routinely to evaluate the effects of treatment. Statistical calculations were done using StatView software (Abacus Concepts, Berkeley, CA ).
Systemic tumor model
Female severe immune -deficient mice ( beige /SCID ) were purchased from Harlan ( Indianapolis, IN ). All animals were kept in an isolator /barrier maintained facility. An intravenous injection of 1Â10 7 NCI -H69 cells was given and the animals were randomized ( i.e., 10 mice per group ). Ten days later, four of the treated groups received a single intravenous injection of 5Â10 10 particles of ZZCB or IACB. After another week, two of these treated groups received a second dose of 5Â10 10 particles of ZZCB or IACB. Starting 40 days after cell injection, groups were monitored three times a week. Animals were scored gross anatomically for tumor burden and survival plotted against time after injection ( Kaplan -Meier survival function ). Survival function across treatment groups was compared using log rank test analysis using Statview software (Abacus Concepts ). Differences in survival were considered statistically significant with P values <.05. On day 90 after cell injection, all animals were 
RESULTS
Interferon produced from IACB is biologically active
To evaluate the expression of interferon, Hep G2 cells were infected with increasing particle concentrations of IACB. At the time points indicated, supernatant samples were taken and assayed for interferon. The data (Fig 1 ) indicate that there was a time -dependent and viral dose -dependent increase in interferon expression. Secretion of interferon was detected 10 hours after infection and was found to increase for an additional 62 hours. Purified virus was found to be free of any detectable amount of residual interferon, indicating that the amount of this cytokine observed in these cell supernatants was due to de novo synthesis. By 72 hours after infection, interferon protein concentrations up to 8 g/ mL were present in supernatants of cells transduced with the highest viral concentration of IACB. This suggested that it should be possible to produce high local concentrations of recombinant interferon by using this virus. To determine if interferon thus produced was biologically active, supernatants from infected cells were tested for antiviral activity. Supernatants from these cells showed a dose -dependent increase in antiviral activity ( Fig 2) , such that the specific activity of interferon, measured as international units per milligram of protein, remained constant at different concentrations of the virus used.
To test whether interferon 2b was expressed in vivo, Buffalo rats were injected intravenously with 1Â10 11 particles of IACB. Serum taken from one animal at different times, as indicated, was tested for both the levels of interferon and whether it was biologically active ( Fig 3 ) . Interferon protein was detected in this animal within 3 hours. By day 5, about 80 ng /mL of interferon could be detected in the serum. It stayed at this level until day 15 and started to decline thereafter, so that by day 30, it was only 300 pg /mL. Because antiviral activity in these samples followed the same profile as the amount of interferon, it suggested that the recombinant protein expressed in vivo was biologically active. A specific activity of 2.5Â10 8 international units /mg protein produced was similar at the different times indicated after injection and was comparable to the specific activity of Intron A.
Biodistribution after IACB treatment
To identify where the interferon was produced in vivo after IACB administration, immunocompetent ICR mice were injected intravenously with a dose of 1Â10 10 particles. On days 2, 7, and 14 after treatment, liver, lung, kidney, and spleen tissues were harvested and assayed for viral DNA and interferon mRNA by real -time quantitative PCR and RT-PCR, respectively ( Fig 4 ) . On day 2, most of the viral DNA were found in liver and spleen, with 10-fold less in the lung and 100 -fold less in kidney. Vector DNA levels decreased by approximately 10-fold on day 14 in all organs tested. Analysis of mRNA levels indicates a greater level of expression in liver with 100-fold more transcripts ( per organ) than the spleen and nearly 10,000 times more than in lung or kidney. Although liver mRNA levels did not change very much by day 7, they decreased 100 -fold by day 14. Interferon protein levels in sera were 8 and 18 ng /mL on days 2 and 7, respectively, and none was detected by day 14.
To test if the interferon protein levels in different tissues followed a similar pattern, mice were injected intravenously with a single dose of increasing particle concentration of IACB and compared to subcutaneous administration of Intron A (Fig 5 ) . There was a concentration-dependent increase in the expression of interferon in all the tissues. The biodistribution of interferon protein expressed with the administration of IACB differed considerably from that seen with protein delivery. Concentration in liver and spleen was substantially higher in IACB -treated animals than in the mice dosed with Intron A. Elevated levels of interferon in liver and spleen would be expected based on the biodis- IQBAL AHMED, JOHNSON, DEMERS, ET AL: CANCER GENE THERAPY FOR CANCER tribution of the vector DNA. Because circulating interferon protein is known to be cleared by the kidney, high concentrations in kidney extracts were observed. A bias toward higher concentrations in liver and spleen was observed with IACB administration.
Suppression of tumor growth
The efficacy of IACB in suppressing tumor growth was tested in athymic nude mice bearing human tumor xenografts generated from one of the four different cell lines. Upon formation of the established tumors, with sizes of approximately 80 mm 3 , these animals were injected intratumorally with PBS ( vehicle control ), control viruses ( ZZCB or GFCB ), or IACB at 10 10 particles per dose, given six times over a period of 2 weeks. PBS -treated tumors grew progressively until the animals were sacrificed. During the same period, there was a small reduction in the size of tumors treated with the control adenovirus. Treatment with IACB resulted in a significant reduction of tumor size in all the xenografts studied. Tumors derived from Hep 3B cells, injected intratumorally with IACB, showed a significant reduction in size, compared with PBS -or control adenovirus -injected tumors at each of the time points observed ( Fig  6A ) . On day 49, in comparison with the PBS -injected tumors, there was a 40% decrease (P=.0003) in the size of tumors injected with control adenovirus and a 90% decrease ( P <.0001) in the size of tumors injected with IACB. Sera taken from IACB -treated animals and assayed for interferon on days 31, 44, and 58 showed 1.9± 3, 2.8 ± 5, and 0.34 ± 0.17 ng /mL, respectively. Thus, intratumoral administration of IACB cannot only lead to a localized inhibition of tumor growth, it can also lead to systemic circulation of interferon that may contribute to the overall therapeutic effect. Intratumoral injection of LN229 -derived tumors with GFCB resulted in a 40% reduction of tumor growth on day 38 ( P= .008), compared with the PBS -injected tumors ( Fig  6B ) . In contrast, IACB -treated tumors were reduced by 90% compared with the PBS -injected ones on day 38 ( P< .0001 ) and reduced further until day 52 of the study. Sera taken from IACB -treated animals on days 16, 31, 44, and 59 showed 3.7 ± 0.5, 7.8± 7, 2.6 ± 3, and 1.7 ± 2 ng/mL, respectively.
U87MG -derived tumors in nude mice were injected with PBS, control adenovirus (GFCB), or IACB ( Fig 6C) . On day 20 after cell injection, there was a small decrease in GFCB -treated tumors, whereas the IACB -treated tumors did not show any further growth. On day 28, in comparison with PBS -treated tumors, there was a 71% reduction in the size of GFCB-treated tumors and a 95% reduction in tumor size in IACB -injected tumors ( P <.0001 ). Tumors treated with IACB kept regressing, so that by day 48, five of five animals in this group were tumor-free and remained so for the duration of the study ( day 55 ). Sera from these animals were taken and assayed for interferon. On days 16, 31, 44, and 58, there was 3.3 ± 3, 3± 2.9, 0.5 ± 0.17, and 0.6 ± 0.7 ng/ mL of interferon, respectively, in the sera of IACB -treated animals, suggesting the systemic circulation of interferon after intratumoral administration.
K562 -derived subcutaneous tumors were injected intratumorally with PBS, ZZCB, or IACB (Fig 6D ) . On day 39, in comparison with PBS -injected tumors, there was a 46% decrease in size of tumors injected with ZZCB (P= .01 ), whereas a 98% decrease in tumor size with IACB was observed ( P <.0001 ). There was a further decrease in the tumor size of IACB -treated tumors, so that by day 49, three of five animals were tumor-free, whereas the other two had 168 mm 3 size tumors. Sera taken from IACB -treated animals on day 34 showed 13± 18 ng /mL of interferon.
To test if intravenous administration of IACB may be effective in suppressing tumor growth, nude mice carrying xenografts of Hep 3B ( Fig 7A ) or U87MG ( Fig 7B ) were studied. With the Hep 3B -derived tumors, PBS, or GFCB treatment resulted in a similar profile of tumor growth. A dose -dependent decrease in tumor size was observed with the administration of IACB. On day 40, tumors from animals treated with 1Â10 10 particle were reduced by 73% ( P <.0001), whereas those with 7Â10 10 particles were reduced by 82% (P < .0001 ). A greater reduction in tumor size was observed with the larger dose until day 55.
We also wanted to evaluate how differences in the route of administration can affect tumor growth in vivo. A comparison of the intratumoral or intravenous administration of IACB on U87MG tumors is shown in Figure 7B . On day 34, animals injected intravenously with GFCB showed a 12% reduction in tumor size, whereas intratumoral administration of GFCB at the same dosage caused a 47% reduction in tumor size ( P= .007) compared with the PBS -injected animals. Intravenous administration of IACB caused 86% decrease in tumor size (P < .0001 ), whereas intratumoral injection at the same dosage resulted in 95% suppression in tumor size ( P< .0001 ), with four of eight animals being tumor-free. On day 37, five of eight animals were tumorfree and remained so until day 55 of the study. Three of these animals had tumors grow back again. As was seen with the Hep 3B tumors, intravenous administration was not as effective in suppressing the tumors as the intratumoral administration. This could be due to either the local effects of the virus, the high local concentration of human interferon 2b, or the differences in the number of injections each received.
To test the efficacy of IACB in a disseminated model, beige /SCID mice were injected intravenously with human small cell lung carcinoma ( NCI -H69 ) cells. Ten days later, the treatment groups received a single intravenous dose of ZZCB or IACB. One week later, two of these groups received a second dose of ZZCB or IACB. Untreated or control adenovirus -treated animals started to die about 47 days after cell injection. Visible tumors developed in ovaries and adrenals of these animals. Microscopic tumors were detected in liver, kidney, and brain. Survival was significantly prolonged ( P <.0001 ) in all IACB -treated groups compared to untreated or ZZCB -treated animals. On day 68, the survival rate in the high or low dose of IACB -treated animals was 80% and 70%, respectively, whereas all the animals in control groups were dead. All surviving animals that were sacrificed on day 90 after cell injection showed some tumor burden sequestered primarily in the lymph nodes. 
DISCUSSION
We have described the utility of using interferon 2b in a gene therapy modality in this report. After the administration of a single dose, systemic circulation of high amounts of interferon was observed for at least 2 weeks. Intratumoral, as well as intravenous, administration of IACB was effective in suppressing tumor growth of tumors derived from different types of cancer. Both primary and metastatic tumor models were responsive to the action of interferon.
We have recently described interferon gene delivery with the use of an adenoviral vector that was deleted in early region 1 and parts of early regions 3 and 4. 7 The vector used in this report, in contrast, is deleted in early region 1 and part of early region 3. Retaining the early region 4 domain was shown to yield a longer duration of expression from the CMV immediate early promoter. 19 Interferon produced with this vector was found to be biologically active both in vitro and in vivo (Figs 1-3 ). Use of a strong promoter, such as the CMV promoter used in our studies, resulted in secretion of a large amount of protein (Figs 1-3 ) , which is likely to provide increased and sustained local concentrations of interferon. Owing to the tropism of adenovirus after intravenous delivery, there was greater distribution of vector DNA, interferon 2b mRNA, and interferon 2b protein in liver and spleen ( Fig 5 ) . This profile differed from that observed with interferon protein delivery, where lung and kidney had the highest concentration of the protein. A high concentration in kidney in both the treatments was to be expected because that is the route of clearance of this protein. It remains to be seen if a different biodistribution profile observed with IACB as opposed to protein delivery (Fig 5 ) may provide a better therapeutic effect.
We have used four different cell lines, derived from different types of human cancer, to generate and establish subcutaneous tumors that were allowed to grow up to 80 mm 3 before initiating treatment. This is a rigorous test because many earlier reports using interferon gene therapy used either nonestablished or small-sized tumors. 6 In addition to its antiproliferative action, interferon also exhibits antiangiogenic 20 and immunomodulatory effects. 21 This is likely to increase the therapeutic potential due to the bystander effect on the transplanted human xenograft cells. Intratumoral injections were shown to result in systemic circulation of interferon, which is likely to increase its therapeutic effect, but because the human interferon 2b used in this report is not active on rodent cells, the full benefit of its action probably was not achieved. Therefore, the actual effect in a clinical situation is likely to be greater than that observed in our studies. It must be noted that intravenous delivery was also effective in suppressing tumor growth, although to a lesser extent than when the vector was injected inratumorally. In addition, the effectiveness of interferon gene delivery in the metastatic model generated with H69 cells (Fig 8 ) suggests that it may be possible to use interferon gene therapy for the treatment of metastatic tumors, without recourse to actual localization of tumors in internal organs.
Interferon exerts its effect through interaction with cell cycle regulatory proteins and through immunomodulation. That interferon gene therapy was effective in both nude ( deleted for T cells ) and beige / SCID (deleted for NK, T, and B cells ) mice points to the fact that interferon can exert its antitumor activity even in the absence of T cells. This is in contradiction to the observations on murine interferon 10, 11 and murine interferon , 22 where T cells were suggested to be obligatory for interferon action.
It is interesting to note that interferon can act on a wide spectrum of tumor cells, derived from different tissues that have undergone different genetic alterations. Hep 3B cells that are derived from hepatocellular carcinoma are p53 -null and negative for retinoblastoma protein and are therefore without the effect of the two major suppressors of tumor growth. U87MG and LN229 are both derived from human glioblastoma, which show frequent deletion in chromosome 9, near the region containing interferon alpha gene cluster.
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U87MG is deleted for PTEN, whereas a wild -type allele is found in LN229. K562 cells are derived from chronic myelogenous leukemia and are p53 -null. H69 cells are from small cell lung carcinoma and are p53 -null and mutated for retinoblastoma protein. Regardless of the differences in intracellular milieu, interferon gene therapy was found to exert an antitumor effect.
Therapy with interferon protein involves five daily injections per week for 1 month followed by three injections per week for 11 months. This regimen is often associated with toxicity. A frequent administration of interferon protein is required because of its short half -life in serum. Peak serum levels are observed within 1-8 hours after protein injection via intravenous, subcutaneous, or intramuscular routes, and within 24 hours, there is no detectable interferon. 24 This results in fluctuating serum levels of interferon during treatment. In contrast to this, a constitutive and sustained local concentration of interferon, such as that provided in a gene therapy modality, seems to offer an attractive alternative. A side -by -side comparison of consensus interferon protein or gene therapy in a subcutaneous tumor model in nude mice showed a striking difference in the two approaches. Complete tumor suppression was achieved with gene delivery, whereas protein delivery had very little effect on tumor growth. 9 It is quite likely that gene delivery approaches, coupled with regulatable promoters that can alter the level and kinetics of a therapeutic protein, 25, 26 will provide a more effective means of exploiting antitumor properties of interferon.
